GILDGilead SciencesSigning up patients
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 695 (planned)
- Started
- Apr 4, 2025
- Main results expected
- Oct 2029
- Fully finished
- Oct 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: Up to 4.5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06801834 · record last updated 2026-10-20 · checked 2026-11-09 15:47 UTC